Table 2.
Clinical Parameters of the TxG Patients and the Control Patients
| TxG patients (n = 10) | Control patients (n = 22) | |
|---|---|---|
| Donor sex (female/male) | 5:5 | 9:13 |
| Donor age | 65 ± 10.7 years⁎ | 53 ± 13.5 years⁎ |
| Donor serum creatinine at explantation | 94.5 ± 24.26 μmol/L | 97.7 ± 41.01 μmol/L |
| Cold ischemia time | 11.7 ± 7.73 hours | 15.2 ± 6.40 hours |
| Number of HLA mismatches | 3.5 ± 1.43⁎ | 2.0 ± 1.68⁎ |
| Panel reactive antibodies present at time of transplantation | 0 (0%) | 1 (5%) |
| Recipient sex (female/male) | 4:6 | 15:7 |
| Recipient age | 54 ± 11.4 years | 50 ± 13.0 years |
| Initial graft function | 6 (60%) | 13 (59%) |
| Lowest serum creatinine within the first 6 weeks after transplantation | 190.2 ± 63.41 μmol/L⁎ | 128.2 ± 59.01 μmol/L⁎ |
| Initial immunosuppression with cyclosporin A | 8 (80%) | 17 (77%) |
| Initial immunosuppression with tacrolimus | 2 (20%) | 4 (18%) |
| Initial immunosuppression with rapamycin | 1 (10%) | 1 (5%) |
| Initial immunosuppression with mycophenolate mofetil | 7 (70%) | 12 (55%) |
| Initial immunosuppression with corticosteroids | 9 (90%) | 21 (95%) |
⁎
P < 0.05 in Mann-Whitney U-test.